. Author manuscript; available in PMC: 2011 Jan 3.

Published in final edited form as: Nat Med. 1995 Oct;1(10):1017–1023. doi: 10.1038/nm1095-1017

Table 3.

Cellular ADA activity at 18 months after gene transduction

	ADA^a	PNP^a	ADA/PNP
G418-resistant CFU-GM colonies
Patient 1	24,051.0	28,038.0	0.86
Normal^b	4,694.0	7,730.0	0.61
Unselected T lymphocytes ^c
Patient 1	99.0	4,262.0	0.02
Patient 2	65.7	2,366.0	0.03
Patient 3	29.3	1,996.0	0.01
ADA- brother of Patient 2^c	60.6	2,212.0	0.03
ADA- SCID patients (n = 13)^c	41.3 ± 33.4	3,710 ± 1,678	0.01
Normal	2,047 ± 1,360	3,007 ± 824	0.68

U, nmol hr^-1 per mg protein; PNP, purine nucleoside phosphorylase.

CD34+ cells from the bone marrow of a normal donor were transduced with the LN retroviral vector and grown in CFU-GM assay with 0.9 mg ml^-1 G418.

T lymphocytes were cultured by a modification of Arredondo-Vega³¹; blood mononuclear cells were grown for 2 days in RPMI 1640, 15% heat-inactivated fetal bovine serum containing 5 μg ml^-1 PHA, then in medium lacking PHA, containing 50 U ml^-1 IL-2. After 10–14 days, 10⁷ cells were harvested for enzyme assay.

^dUnder treatment with PEG-ADA, but not with ADA-transduced cells.